Ad
related to: boston scientific lumenis acquisition system in america- Product Indications
Read More About Indications,
Safety, and Warnings
- Patient Resources
Get Personal Support And Resources
To Find The Answers You Need.
- Product Indications
Search results
Results From The WOW.Com Content Network
Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.
Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, [2] is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular ...
With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share).
Boston Scientific has made a strong move deeper into the business of electrophysiology -- the study of electrical phemomena, and how they are related to the functions of the body. The company ...
Kenneth Frank Binmoeller is a medical doctor and author of multiple scientific contributions [1] and over 300 publications, [2] [3] as well as the inventor of the lumen-apposing metal stent (LAMS) [4] [5] and AXIOS System. [6] [7] These are medical devices used to relieve blockages while creating a direct connection between two bodily ...
The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.
Acquisition offer by Boston Scientific [ edit ] On December 5, 2005, Boston Scientific made a surprise unsolicited $24.6 billion bid to acquire Guidant, offering $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share.
Boston Scientific forecast a full-year profit on Wednesday that was largely ahead of analysts' estimates and said the U.S. health regulator has approved its heart device, sending the company's ...